Efficacy and Adherence to Palbociclib in Advanced Breast Cancer in Romania
Author Information
Author(s): Lungulescu Cristian Virgil, Camen Georgiana-Cristiana, Naidin Mihaela-Simona, Berisha Tradian-Ciprian, Bita Andrei, Dinescu Venera-Cristina, Buteica Sandra Alice, Dimulescu Marina-Daniela, Volovat Simona Ruxandra, Turcu-Stiolica Adina
Primary Institution: University of Medicine and Pharmacy of Craiova, Romania
Hypothesis
The study aims to evaluate the efficacy, safety, and adherence to Palbociclib in combination with either an aromatase inhibitor or fulvestrant in HR+/HER2− breast cancer patients from Romania.
Conclusion
The study found no significant differences in overall survival between treatment combinations of Palbociclib with aromatase inhibitors and fulvestrant.
Supporting Evidence
- Median time to treatment discontinuation was 19 months.
- Median overall survival was 39 months.
- Adherence to Palbociclib was high with a mean of 0.91.
- 12-month TTD rates were higher for Palbociclib combined with AI than with fulvestrant.
- Median OS for Palbociclib plus fulvestrant was 50.8 months.
Takeaway
This study looked at how well a cancer drug called Palbociclib works for women with a specific type of breast cancer in Romania, and it found that both treatment options are good choices.
Methodology
A retrospective analysis of reimbursed Palbociclib prescriptions was conducted using data from the Romanian Health Insurance House from 2018 to 2023.
Potential Biases
Limited data access may introduce bias in interpreting treatment outcomes.
Limitations
The study was limited to a specific region in Romania and lacked comprehensive data on patient history and treatment tolerability.
Participant Demographics
98% female, median age 62 years (IQR, 53–70).
Statistical Information
P-Value
0.249
Confidence Interval
95%CI, 19.3–24.9 months for TTD; 95%CI, 25.5–50.9 months for OS.
Statistical Significance
p=0.249
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website